First-in-human study of the safety and efficacy of TOL101 induction to prevent kidney transplant rejection

American Journal of Transplantation

Volumn 14, Issue 6, 2014, Pages 1346-1355

  Flechner, S M ^a   Mulgoankar, S ^b   Melton, L B ^c   Waid, T H ^d   Agarwal, A ^e   Miller, S D ^f   Fokta, F ^g   Getts, M T ^g   Frederick, T J ^g   Herrman, J J ^g   Puisis, J P ^g   O'Toole, L ^g   Sung, R ^h   Shihab, F ⁱ   Wiseman, A C ^j   Getts, D R ^f,g  

^a LERNER RESEARCH INSTITUTE   (United States)

^b SAINT BARNABAS MEDICAL CENTER   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g Tolera Therapeutics Inc   (United States)

^h UNIVERSITY OF MICHIGAN   (United States)

ⁱ UNIVERSITY OF UTAH   (United States)

^j UNIVERSITY OF COLORADO   (United States)

more..

Author keywords

Acute rejection; induction; kidney transplantation

Indexed keywords

ANTIHISTAMINIC AGENT; CREATININE; MONOCLONAL ANTIBODY; STEROID; TOL 101; UNCLASSIFIED DRUG; VITAMIN D; TOL101;

ABDOMINAL DISEASE; ABDOMINAL PAIN; ADULT; ANEMIA; ARTICLE; BACKACHE; BLURRED VISION; CD3+ T LYMPHOCYTE; CHILL; CLINICAL ARTICLE; CONNECTIVE TISSUE DISEASE; CONSTIPATION; COUGHING; CREATININE BLOOD LEVEL; DEHYDRATION; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FIRST IN HUMAN STUDY; GENITAL SYSTEM DISEASE; GRAFT RECIPIENT; HEADACHE; HEMATURIA; HOSPITAL INFECTION; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; INSOMNIA; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; LEUKOPENIA; MALE; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; NAUSEA; OROPHARYNX PAIN; PAIN; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PRURITUS; RASH; SCROTAL PAIN; SIDE EFFECT; SKIN DISEASE; TACHYCARDIA; TREMOR; UROGENITAL TRACT DISEASE; URTICARIA; VITAMIN BLOOD LEVEL; VOMITING; CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAFT REJECTION; KIDNEY TRANSPLANTATION; MIDDLE AGED;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED;

EID: 84901352884     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12698     Document Type: Article

References (28)

1. Nankivell BJ, Alexander SI., Rejection of the kidney allograft. N Engl J Med 2010; 363: 1451-1462.
2. Dierselhuis M, Goulmy E., The relevance of minor histocompatibility antigens in solid organ transplantation. Curr Opin Organ Transplant 2009; 14: 419-425.
3. Archbold JK, Ely LK, Kjer-Nielsen L, et al. T cell allorecognition and MHC restriction-A case of Jekyll and Hyde ? Mol Immunol 2008; 45: 583-598. (Pubitemid 47498588)
4. Halloran PF., Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715-2729. (Pubitemid 39665325)
5. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770-781. (Pubitemid 41215486)
6. Flechner SM., Sirolimus in kidney transplantation indications and practical guidelines: De novo sirolimus based therapy without calcineurin inhibitors. Transplantation 2009; 87: S1-S6.
7. Webster AC, Playforde G, Higgins G, Chapman JR, Craig JC., Interleukin 2 receptor antagonists for renal transplant recipients: A meta-analysis of randomized trials. Transplantation 2004; 77: 166-176. (Pubitemid 38155741)
8. Patlola V, Zhong X, Reed GW, Mandelbrot DA., Efficacy of anti-IL-2 receptor antibodies compared to no induction and to antilymphocyte antibodies in renal transplantation. Am J Transplant 2007; 7: 1832-1841. (Pubitemid 46905449)
9. Cai J, Terasaki PI., Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: An analysis of United Network for Organ Sharing registry data. Transplantation 2010; 90: 1511-1515.
10. Nashan B., Antibody induction therapy in renal transplant patients receiving calcineurin-inhibitor immunosuppressive regimens. Biodrugs 2005; 19: 39-46. (Pubitemid 40432506)
11. Wagner SJ, Brennan DC., Induction therapy in renal transplant recipients: How convincing is the current evidence ? Drugs 2012; 72: 671-683.
12. Brennan DC, Daller JA, Lake KD, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006; 355: 1967-1977. (Pubitemid 44708016)
13. Hanaway MJ, Woodle ES, Mulgaonkar S, et al. Alemtuzumab induction in renal transplantation. N Engl J Med 2011; 364: 1909-1919.
14. Guttmann RD, Caudrelier P, Alberici G, Touraine JL., Pharmacokinetics, foreign protein immune response, cytokine release, and lymphocyte subsets in patients receiving thymoglobuline and immunosuppression. Transplant Proc 1997; 29: 24S-26S.
15. Broeders N, Wissing KM, Crusiaux A, Kinnaert P, Vereerstraeten P, Abramowicz D., Mycophenolate mofetil, together with cyclosporin A, prevents anti-OKT3 antibody response in kidney transplant recipients. J Am Soc Nephrol 1998; 9: 1521-1525. (Pubitemid 28354564)
16. Kaufman DB, Leventhal JR, Axelrod D, et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: Comparison with basiliximab induction-Long-term results. Am J Transplant 2005; 5: 2539-2548.
17. Matsumoto Y, Tsuchida M, Hanawa H, Abo T., Successful prevention and treatment of autoimmune encephalomyelitis by short-term administration of anti-T-cell receptor alpha beta antibody. Immunology 1994; 81: 1-7. (Pubitemid 24249824)
18. Sempe P, Bedossa P, Richard MF, Villa MC, Bach JF, Boitard C., Anti-alpha/beta T cell receptor monoclonal antibody provides an efficient therapy for autoimmune diabetes in nonobese diabetic (NOD) mice. Eur J Immunol 1991; 21: 1163-1169.
19. Khariwala SS, Knott PD, Dan O, Klimczak A, Siemionow M, Strome M., Pulsed immunosuppression with everolimus and anti-alphabeta T-cell receptor: Laryngeal allograft preservation at six months. Ann Otol Rhinol Laryngol 2006; 115: 74-80. (Pubitemid 43132444)
20. Siemionow MZ, Izycki DM, Zielinski M., Donor-specific tolerance in fully major histocompatibility major histocompatibility complex-mismatched limb allograft transplants under an anti-alphabeta T-cell receptor monoclonal antibody and cyclosporine A protocol. Transplantation 2003; 76: 1662-1668. (Pubitemid 38032410)
21. Waid TH, Lucas BA, Thompson JS, et al. Treatment of renal allograft rejection with T10B9.1A31 or OKT3: Final analysis of a phase II clinical trial. Transplantation 1997; 64: 274-281. (Pubitemid 27332672)
22. Waid TH, Lucas BA, Thompson JS, et al. Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients. Transplantation 1992; 53: 80-86.
23. Beelen DW, Graeven U, Schulz G, et al. Treatment of acute graft-versus-host disease after HLA-partially matched marrow transplantation with a monoclonal antibody (BMA031) against the T cell receptor. First results of a phase-I/II trial. Onkologie 1988; 11: 56-58. (Pubitemid 18076147)
24. Haynes BF, Fauci AS., The differential effect of in vivo hydrocortisone on the kinetics of subpopulations of human peripheral blood thymus-derived lymphocytes. J Clin Invest 1978; 61: 703-707.
25. Getts DR, Getts MT, McCarthy DP, Chastain EM, Miller SD., Have we overestimated the benefit of human(ized) antibodies ? MAbs 2010; 2: 682-694.
26. Flechner SM, Goldfarb DA, Fairchild R, et al. A randomized prospective trial of low dose OKT3 to prevent rejection and minimize side effects in recipients of kidney transplants. Transplantation 2000; 69: 2374-2381. (Pubitemid 30409006)
27. Nashan B, Moore R, Amlot P, et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350: 1193-1198. (Pubitemid 127445091)
28. Getts DR, Shankar S, Chastain EM, et al. Current landscape for T-cell targeting in autoimmunity and transplantation. Immunotherapy 2011; 3: 853-870.